183 related articles for article (PubMed ID: 18333864)
1. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Jenkins TM; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):38-46. PubMed ID: 18333864
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
[TBL] [Abstract][Full Text] [Related]
3. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):47-53. PubMed ID: 18333865
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc: in vitro assessment of drug-drug interaction potential.
Hyland R; Dickins M; Collins C; Jones H; Jones B
Br J Clin Pharmacol; 2008 Oct; 66(4):498-507. PubMed ID: 18647303
[TBL] [Abstract][Full Text] [Related]
5. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
[TBL] [Abstract][Full Text] [Related]
8. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.
Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):19-26. PubMed ID: 18333862
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
Abel S; van der Ryst E; Rosario MC; Ridgway CE; Medhurst CG; Taylor-Worth RJ; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):5-18. PubMed ID: 18333861
[TBL] [Abstract][Full Text] [Related]
10. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
11. The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.
Adkison KK; Shachoy-Clark A; Fang L; Lou Y; Otto VR; Berrey MM; Piscitelli SC
Br J Clin Pharmacol; 2006 Sep; 62(3):336-44. PubMed ID: 16934050
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
Mora-Peris B; Croucher A; Else LJ; Vera JH; Khoo S; Scullard G; Back D; Winston A
J Antimicrob Chemother; 2013 Jun; 68(6):1348-53. PubMed ID: 23364475
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
[TBL] [Abstract][Full Text] [Related]
15. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
Soriano V; Poveda E
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
[TBL] [Abstract][Full Text] [Related]
18. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Waters L; Jackson A; Else L; Rockwood N; Newell S; Back D; Nelson M; Gazzard B; Boffito M
Antivir Ther; 2015; 20(2):157-63. PubMed ID: 24963558
[TBL] [Abstract][Full Text] [Related]
19. A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects.
Chan PL; Weatherley B; McFadyen L
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):76-85. PubMed ID: 18333869
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
Rosario MC; Jacqmin P; Dorr P; James I; Jenkins TM; Abel S; van der Ryst E
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):86-94. PubMed ID: 18333870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
